In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
Publication|Videos|August 30, 2024
DVCR's Multi-Site Model
Author(s)Dr. Vince Clinical Research
Korey Nevitt (Executive Director, Site Partnerships) talked with ACT about what makes Dr. Vince Clinical Research (DVCR) solutions for clinical pharmacology and multi-site studies unique.
Learn More About:
- Their focus on quality and customer service
- Their lead site model and its support for sponsors
- How they anticipate and manage problems for multi-site trials from start to finish
Additional Resources
Webinar
Missed our recent webinar, ’Accelerating Clinical & Drug Development Timelines with AI’? The recording is now available—discover how AI is transforming drug discovery now with industry leaders from Dr. Vince Clinical Research, Enveda Biosciences, and Clario.
Brochure
DVCR would like to serve as Your Full-Service CRO™. Explore how our team of experienced early clinical development professionals can support your research needs in our
Video
DVCR is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas.
Related to this article
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
Trending on Applied Clinical Trials Online
1
How a Platform Approach Can Scale AI’s Impact in Life Sciences
2
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
3
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
4
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
5